Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Yufang WangSchool of Pharmaceutical Sciences, Hebei Medical University Shijiazhuang 050017 China shiqingwen405@163.com.
Yan FuSchool of Pharmaceutical Sciences, Hebei Medical University Shijiazhuang 050017 China shiqingwen405@163.com.
Yeying LiNew Drug Research & Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering & Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City Shijiazhuang 050015 China luxinhua89@yeah.net.
Ruolan LiNew Drug Research & Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering & Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City Shijiazhuang 050015 China luxinhua89@yeah.net.
Xuexia ZhangNew Drug Research & Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering & Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City Shijiazhuang 050015 China luxinhua89@yeah.net.
Mei DongHebei Key Laboratory of Forensic Medicine, Collaborative Innovation Center of Forensic Medical Molecular Identification, Hebei Medical University Shijiazhuang 050017 China.
Françoise SauriolDepartment of Chemistry, Queen's University Kingston K7L 3N6 Canada.
Xinhua LuNew Drug Research & Development Center of North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering & Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Key Laboratory for New Drug Screening Technology of Shijiazhuang City Shijiazhuang 050015 China luxinhua89@yeah.net.ORCID https://orcid.org/0000-0001-8132-8697
Zhiyu NiThe Affiliated Hospital of Hebei University, School of Basic Medical Science, Hebei University Baoding 071000 China nizhiyu@hbu.edu.cn.ORCID https://orcid.org/0000-0003-1818-6125
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Twelve new compounds, aspergorakhins A-L (1-12) coupled with one known xanthone leptosphaerin D (13), were isolated from the extract of soil-derived fungus
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
New protein tyrosine phosphatase inhibitors from fungus · full record | OpenQuestion